Policy shifts in Medicare Advantage (MA) ripple through the healthcare ecosystem. Today, January 27, 2026, UnitedHealth Group’s (UNH) stock plummeted 19.57%, closing at $282.83 after shedding $68.81 per share, erasing roughly $80 billion in market capitalization. This dramatic drop, the company’s worst single-day performance in years, stemmed from a toxic mix of disappointing Q4 2025 earnings and a bombshell policy announcement: the Trump administration’s proposal for essentially flat government Medicare payment rates in 2027. Investors fled as the news highlighted deepening profitability pressures amid surging medical utilization trends.
But the real story lies in the policy mechanics driving this crash—a web of regulatory tweaks aimed at curbing overpayments.
What Is Medicare Advantage?
Medicare Advantage, also known as Medicare Part C, represents a private-sector alternative to traditional Original Medicare (Parts A and B). Offered by Medicare-approved insurance companies, these plans must cover all hospital (Part A) and medical (Part B) benefits at least as comprehensively as Original Medicare, but they often bundle in prescription drug coverage (Part D) and extras like dental, vision, hearing aids, gym memberships, and transportation to appointments. The key trade-off: While many plans feature lower out-of-pocket maximums and reduced copays, beneficiaries typically must use in-network providers (e.g., HMOs or PPOs), which can limit choice and require referrals or prior authorizations—contrasting with original Medicare’s broader provider access. As enrollment surpasses half of Medicare beneficiaries, these managed-care models aim to deliver value through coordinated care, though critics highlight network restrictions and variable plan performance year to year.
The Health Policy Behind The UnitedHealth Stock Crash: The 2027 Medicare Advantage Rate Proposal
The crux of the UnitedHealth crash lies in the Centers for Medicare & Medicaid Services’ (CMS) Advance Notice for Calendar Year 2027 Medicare Advantage capitation rates, released January 26, 2026.
For 2027, CMS proposed a net average payment increase of just 0.09%, translating to about $700 million industry-wide—far below the 2-3% growth needed to offset inflation and cost trends. This “flatlining” adjustment reflects underlying cost trends, 2026 quality ratings, and risk model revisions, but nets down to near-zero after offsets.
This is far less than what Wall Street and the insurance companies projected or expected. Shares are also down for CVS and Humana.
A Surgeon’s Perspective: Medicare Advantage Insurers Were Overpaid
A Wall Street Journal investigation revealed that Medicare Advantage (MA) insurers, including UnitedHealth Group, added hundreds of thousands of potentially questionable or unsupported diagnoses to patient records from 2018–2021, generating about $50 billion in extra federal payments over three years. Under the MA risk-adjustment system, private insurers receive higher reimbursements for enrollees diagnosed with serious, costly conditions. To capture these, insurers conduct home visits, review medical charts (sometimes using AI), and pay providers for record access. They can submit additional diagnoses beyond those from patients’ primary doctors, ostensibly to identify overlooked conditions. The WSJ found many such additions lacked follow-up treatment, contradicted treating physicians’ assessments, or were implausible.
Indeed, CMS officials emphasized “improving payment accuracy and sustainability,” tackling longstanding critiques that MA plans are overpaid by 20-30% relative to fee-for-service (FFS) Medicare. Data from MedPAC shows this is to the tune of an extra $76 billion in 2026.
Also, pragmatically, MA plans are also much more aggressive in prior authorization and care delays. This is something we deal with a consistent basis in practice. We can see the patients in clinic but often times it is very difficult to get approval for advanced tests or necessary surgery. This is coverage without actual clinical care.
Path Forward: What Does This Mean For Patients?
With MA enrolling over 54% of Medicare beneficiaries, the proposed 0.09% payment increase—far below the 4-6% analysts expected—could force plans to slash benefits, hike premiums, or exit markets. Seniors might face narrower networks, more prior authorization denials for procedures like fusions, and reduced extras (dental, vision), delaying care and worsening outcomes.
From my operating room, this likely means more difficulty getting patients to surgery as they will be caught in the cost-cutting crossfire. Again, Medicare Advantage is notoriously difficult with prior authorization for our patients. I would not see that improving in the current landscape.
